Prices delayed by at least 15 minutes | Print
Incyte Corp (INCY)
Common SharesThis share can be held in a Dealing accountISALifetime ISAJISASIPP
Company profile
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Address
1801 Augustine Cut-Off
Wilmington
DE
USA
19803
Telephone
+1 302 498-6700
Forecast key dates
Name | Key Date |
---|---|
Incyte Corp First Quarter Earnings Conference Call for 2025 | 2025-04-30T08:00:00 |
Incyte Corp First Quarter Earnings Results for 2025 | 2025-04-30T00:00:00 |
Incyte Corp Fourth Quarter Earnings Conference Call for 2024 | 2025-02-13T08:00:00 |
Incyte Corp Fourth Quarter Earnings Results for 2024 | 2025-02-13T07:00:00 |
Incyte Corp Annual Report for 2024 | 2025-02-13T00:00:00 |
Incyte Corp Third Quarter Earnings Conference Call for 2024 | 2024-10-31T08:00:00 |
Incyte Corp Third Quarter Earnings Results for 2024 | 2024-10-31T07:00:00 |
Incyte Corp Second Quarter Earnings Conference Call for 2024 | 2024-08-01T08:00:00 |
Incyte Corp Second Quarter Earnings Results for 2024 | 2024-08-01T07:00:00 |
Incyte Corp Annual General Meeting for 2024 | 2024-06-14T10:00:00 |
Bank of America Securities 2024 Health Care Conference | 2024-05-15T08:00:00 |
Previous key dates
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.